Clinical and Laboratory Factors Associated with Exchange Transfusion in Neonates with Severe Hyperbilirubinaemia: A Retrospective Cohort Study
- 1Department of Paediatrics, Şanlıurfa Education and Research Hospital, 63200 Şanlıurfa, Türkiye
- 2Department of Paediatrics, Private Hospital, Osmangazi Cad. No:34 Sarigazi, Sancaktepe, 34885 İstanbul, Türkiye
Abstract
Background and Objectives: Exchange transfusion (ET) remains a critical intervention for severe neonatal hyperbilirubinaemia, yet laboratory associations with ET receipt require careful interpretation. We examined characteristics associated with ET and post-procedure laboratory changes. Materials and Methods: This retrospective tertiary-centre cohort included 98 neonates evaluated between January 2020 and December 2025 (65 received ET; 33 did not). A four-covariate logistic regression model assessed associations with ET receipt. Discrimination, bootstrap optimism, cross-validated calibration and an exploratory creatinine-containing model were examined. Results: Peak total serum bilirubin (TSB) was higher among ET recipients than non-recipients (33.69 ± 6.31 versus 26.19 ± 3.64 mg/dL; p < 0.001). In the primary model (n = 98), peak TSB was associated with ET receipt (adjusted odds ratio 1.31 per mg/dL, 95% confidence interval 1.16–1.48; p < 0.001). The apparent area under the receiver operating characteristic curve (AUC) was 0.860, decreasing to 0.837 after bootstrap optimism correction. An exploratory six-covariate model (n = 97) yielded an apparent AUC of 0.874 and an optimism-corrected AUC of 0.836. Creatinine showed an adjusted association (odds ratio 1.58 per 0.1 mg/dL, 95% confidence interval 1.07–2.32), but its incremental AUC was uncertain (difference 0.014, 95% confidence interval −0.022 to 0.053). Following ET, bilirubin, platelet count and total calcium decreased. Conclusions: Peak TSB strongly distinguished infants who received ET, but this association partly reflects the bilirubin-based indication for treatment. Creatinine did not demonstrate a reliable incremental discrimination benefit. These findings reinforce guideline-based ET assessment and post-exchange monitoring, not the adoption of new treatment thresholds or prediction tools.
Related
- Clinical and Laboratory Prediction of Histopathologically Complicated Acute Appendicitis and Associated Surgical Outcomes: A Retrospective Cohort Study
- Clinical, laboratory, operative, and appendiceal morphometric correlates of histopathological appendicitis severity: A retrospective cohort study from Palestine
- Retrospective cross-sectional study of clinical and laboratory profiles of paediatric tuberculosis at Ayder Comprehensive Specialized Hospital, Ethiopia (2018-2021).
- Prevalence and factors associated with hepatitis B surface antibody seroprotection among healthcare workers undergoing laboratory testing at Eastgate Clinic, Windhoek, Namibia: A retrospective cross-sectional study
- Clinical Phenotype and Outcomes of Multisystem Inflammatory Syndrome in Children According to SARS‐CoV‐2 Laboratory Status During 2020–2021: A Retrospective Observational Study
BibTeX
@article{izol2026clinical,
title = {{Clinical and Laboratory Factors Associated with Exchange Transfusion in Neonates with Severe Hyperbilirubinaemia: A Retrospective Cohort Study}},
author = {Aslıhan İzol and Selçuk Yazıcı and Sümeyya Ercan},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218762},
url = {https://www.mdpi.com/2077-0383/15/21/8762},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical and Laboratory Factors Associated with Exchange Transfusion in Neonates with Severe Hyperbilirubinaemia: A Retrospective Cohort Study
AU - Aslıhan İzol
AU - Selçuk Yazıcı
AU - Sümeyya Ercan
PY - 2026
DA - 2026/11/09
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218762
UR - https://www.mdpi.com/2077-0383/15/21/8762
AB - Background and Objectives: Exchange transfusion (ET) remains a critical intervention for severe neonatal hyperbilirubinaemia, yet laboratory associations with ET receipt require careful interpretation. We examined characteristics associated with ET and post-procedure laboratory changes. Materials and Methods: This retrospective tertiary-centre cohort included 98 neonates evaluated between January 2020 and December 2025 (65 received ET; 33 did not). A four-covariate logistic regression model assessed associations with ET receipt. Discrimination, bootstrap optimism, cross-validated calibration and an exploratory creatinine-containing model were examined. Results: Peak total serum bilirubin (TSB) was higher among ET recipients than non-recipients (33.69 ± 6.31 versus 26.19 ± 3.64 mg/dL; p < 0.001). In the primary model (n = 98), peak TSB was associated with ET receipt (adjusted odds ratio 1.31 per mg/dL, 95% confidence interval 1.16–1.48; p < 0.001). The apparent area under the receiver operating characteristic curve (AUC) was 0.860, decreasing to 0.837 after bootstrap optimism correction. An exploratory six-covariate model (n = 97) yielded an apparent AUC of 0.874 and an optimism-corrected AUC of 0.836. Creatinine showed an adjusted association (odds ratio 1.58 per 0.1 mg/dL, 95% confidence interval 1.07–2.32), but its incremental AUC was uncertain (difference 0.014, 95% confidence interval −0.022 to 0.053). Following ET, bilirubin, platelet count and total calcium decreased. Conclusions: Peak TSB strongly distinguished infants who received ET, but this association partly reflects the bilirubin-based indication for treatment. Creatinine did not demonstrate a reliable incremental discrimination benefit. These findings reinforce guideline-based ET assessment and post-exchange monitoring, not the adoption of new treatment thresholds or prediction tools.
SN - 2077-0383
ER -